ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) Director Barry Simon sold 75,000 shares of the stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $12.01, for a total value of $900,750.00. Following the completion of the transaction, the director directly owned 2,850,821 shares of the company's stock, valued at approximately $34,238,360.21. This represents a 2.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
ImmunityBio Stock Performance
Shares of ImmunityBio stock opened at $9.55 on Friday. ImmunityBio, Inc. has a one year low of $1.83 and a one year high of $12.43. The company has a market cap of $9.82 billion, a price-to-earnings ratio of -25.13 and a beta of 0.16. The business's 50 day moving average price is $5.12 and its 200 day moving average price is $3.32.
ImmunityBio (NASDAQ:IBRX - Get Free Report) last released its quarterly earnings data on Monday, March 2nd. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.02. The business had revenue of $38.29 million during the quarter. On average, analysts predict that ImmunityBio, Inc. will post -0.92 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Armistice Capital LLC acquired a new position in ImmunityBio during the 2nd quarter worth approximately $20,497,000. Heights Capital Management Inc. acquired a new position in shares of ImmunityBio during the third quarter worth $16,152,000. Vanguard Group Inc. boosted its stake in shares of ImmunityBio by 26.8% in the third quarter. Vanguard Group Inc. now owns 27,655,205 shares of the company's stock valued at $68,032,000 after purchasing an additional 5,837,898 shares during the period. State Street Corp boosted its stake in shares of ImmunityBio by 45.4% in the fourth quarter. State Street Corp now owns 16,455,703 shares of the company's stock valued at $32,582,000 after purchasing an additional 5,139,890 shares during the period. Finally, Goldman Sachs Group Inc. grew its holdings in ImmunityBio by 439.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 6,152,684 shares of the company's stock valued at $12,182,000 after purchasing an additional 5,012,001 shares in the last quarter. Institutional investors and hedge funds own 8.58% of the company's stock.
Analysts Set New Price Targets
A number of equities research analysts have issued reports on the company. D. Boral Capital reaffirmed a "buy" rating and issued a $23.00 price target on shares of ImmunityBio in a research report on Monday. Jefferies Financial Group raised their target price on shares of ImmunityBio from $8.00 to $9.00 and gave the stock a "buy" rating in a research report on Friday, December 12th. The Goldman Sachs Group reaffirmed a "buy" rating on shares of ImmunityBio in a research note on Monday. HC Wainwright lifted their price objective on ImmunityBio from $10.00 to $15.00 and gave the company a "buy" rating in a report on Monday. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of ImmunityBio in a report on Monday, December 29th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $12.60.
Get Our Latest Stock Analysis on ImmunityBio
ImmunityBio Company Profile
(
Get Free Report)
ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.
Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
